[PDF][PDF] Pentoxifylline: An Immunomodulatory Drug for the Treatment of COVID-19.

HA Dhameliya, VR Thakkar… - Journal of Pure & …, 2020 - pdfs.semanticscholar.org
Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) is causing serious health concerns worldwide. It started as an epidemic in …

[HTML][HTML] Pentoxifylline: a drug with antiviral and anti-inflammatory effects to be considered in the treatment of coronavirus disease 2019

M Ghasemnejad-Berenji, S Pashapour… - Medical Principles and …, 2021 - karger.com
In December 2019, a new coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in …

Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients

BM Hendry, N Stafford, AD Arnold… - Pharmacology …, 2020 - Wiley Online Library
We propose a new hypothesis that the established drug pentoxifylline deserves attention as
a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with …

Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial

H Azizi, N Rouhani, F Shaki… - International …, 2021 - Elsevier
Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory,
anticoagulant, and antiviral effects. The aim of this study was to evaluate the efficacy and …

Treatment of COVID‐19 with pentoxifylline: could it be a potential adjuvant therapy?

F Seirafianpour, S Mozafarpoor, N Fattahi… - Dermatologic …, 2020 - Wiley Online Library
The world is facing a viral pandemic of a new coronavirus called COVID‐19. Pentoxifylline is
a methyl‐xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is …

A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19

G Mostafa-Hedeab, HM Al-Kuraishy, AI Al-Gareeb… - …, 2022 - Springer
The existing pandemic viral infection caused by severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …

Pentoxifylline and Covid-19: A systematic review

D Ramonfaur, CA González-Assad… - medRxiv, 2020 - medrxiv.org
At more than 10 months after the first case of COVID-19 was documented, the understanding
of the pathogenesis of this viral illness is growing on a daily basis. A massive pro …

Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal

SF Assimakopoulos, F Seintis, M Marangos - Medical hypotheses, 2020 - ncbi.nlm.nih.gov
Accumulating evidence suggests that a subgroup of patients with COVID-19 might suffer
from severe complications, such as acute respiratory distress syndrome (ARDS) …

Pentoxifylline effects on hospitalized COVID-19 patients with cytokine storm syndrome: a randomized clinical trial

RM Sarhan, A E. Altyar, A Essam Abou Warda… - Pharmaceuticals, 2023 - mdpi.com
COVID-19 is a fatal, fast-spreading pandemic, and numerous attempts are being made
around the world to understand and manage the disease. COVID-19 patients may develop a …

Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic

F Monji, AAM Siddiquee, F Hashemian - European Journal of …, 2020 - Elsevier
COVID-19 pandemic presents an unprecedented challenge to identify effective drugs for
treatment. Despite multiple clinical trials using different agents, there is still a lack of specific …